ReviewClinical reviews in allergy & immunology2022
Systemic Sclerosis Association with Malignancy.
Review in Clinical reviews in allergy & immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 45 citations in OpenAlex.
- Association between Diagnostic History and Cancer Incidence within 5 Years: A Real-world Observational Analysis.Cancer research communications · 2026Observational
- Article
- PD-1 inhibitor-induced systemic sclerosis with early interstitial lung disease and autoimmune thyroiditis in advanced gastric cancer: a case report and literature review.Frontiers in oncology · 2026Article
- Cancer Risk in Patients With Systemic Sclerosis: A Nationwide Cohort Study in South Korea 2004 to 2021.Arthritis care & research · 2025Article
- Rituximab versus mycophenolate mofetil for cancer risk in systemic sclerosis.Rheumatology (Oxford, England) · 2025Article
- Systemic sclerosis triggered by bleomycin: a 5-year follow-up.EULAR rheumatology open · 2025Article
- PET-CT indications and contributions to diagnosis in the rheumatology clinic: a retrospective analysis.Clinical rheumatology · 2025Article
- Article
- Cancer Risk in Autoimmune and Immune-Mediated Diseases: A Narrative Review for Practising Clinicians.Journal of clinical medicine · 2025Review
- Malignancy in Systemic Sclerosis: A Multicenter Retrospective Study.Biomedicines · 2025Article
- Quantitative N-glycoproteomic analysis reveals glycosylation signatures of plasma immunoglobulin G in systemic sclerosis.Frontiers in immunology · 2025Article
- Risk of cancer and conventional syntethic DMARDS: A narrative review.Northern clinics of Istanbul · 2025Article
- Editorial: Understanding scleroderma: symptoms, causes, treatment options, and advanced diagnostic techniques.Frontiers in immunology · 2025Article
- Autoimmune disease-associated lymphomas: research progress and review.Frontiers in immunology · 2025Review
- Widespread mutagenesis and chromosomal instability shape somatic genomes in systemic sclerosis.Nature communications · 2024Article
- Autoantibodies, cutaneous subset and immunosuppressants contribute to the cancer risk in systemic sclerosis.RMD open · 2024Article
- Exploring the relationship between morphea and malignancy: a decade-long single-center study of 204 patients.Archives of dermatological research · 2024Article
- High resolution computed tomography in systemic sclerosis: From diagnosis to follow-up.Rheumatology and immunology research · 2024Article
- Review
- Anti-Th/To Antibodies in Scleroderma: Good Prognosis or Serious Concern?Journal of clinical medicine · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The association of systemic sclerosis (SSc) and cancer is well known from several decades suggesting common genetic and environmental risk factors involved in the development of both diseases. Immunosuppressive drugs widely used in SSc may increase the risk of cancer occurrence and different SSc clinical and serological features identify patients at major risk to develop malignancy. In this context, among serological features, presence of anti-RNA polymerase III and anti-topoisomerase I autoantibodies seems to increase cancer frequency in SSc patients (particularly lung and breast cancers). Lung fibrosis and a long standing SSc pulmonary involvement have been largely proposed as lung cancer risk factors, and the exposure to cyclophosphamide and an upper gastrointestinal involvement have been traditionally linked to bladder and oesophagus cancers, respectively. Furthermore, immune checkpoint inhibitors used for cancer therapy can induce immune-related adverse events, which are more frequent and severe in patients with pre-existing autoimmune diseases such as SSc. The strong association between SSc and cancer occurrence steers clinicians to carefully survey SSc patients performing periodical malignancy screening. In the present review, the most relevant bilateral relationships between SSc and cancer will be addressed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.